Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $40 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $12 | $20 | $10 |
| Gross Profit | $0 | -$12 | $20 | -$10 |
| % Margin | – | – | 50% | – |
| R&D Expenses | $19,634 | $20,258 | $20,545 | $19,330 |
| G&A Expenses | $6,340 | $5,973 | $5,261 | $5,108 |
| SG&A Expenses | $6,340 | $5,973 | $5,271 | $5,108 |
| Sales & Mktg Exp. | $0 | $0 | $10 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25,974 | $26,231 | $25,816 | $24,438 |
| Operating Income | -$25,974 | -$26,231 | -$25,806 | -$24,438 |
| % Margin | – | – | -64,515% | – |
| Other Income/Exp. Net | $2,882 | $3,261 | $3,571 | $4,261 |
| Pre-Tax Income | -$23,092 | -$22,970 | -$22,235 | -$20,177 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23,092 | -$22,970 | -$22,235 | -$20,177 |
| % Margin | – | – | -55,587.5% | – |
| EPS | -0.9 | -0.89 | -0.86 | -0.78 |
| % Growth | -1.1% | -3.5% | -10.3% | – |
| EPS Diluted | -0.9 | -0.89 | -0.86 | -0.78 |
| Weighted Avg Shares Out | 25,755 | 25,692 | 25,796 | 25,767 |
| Weighted Avg Shares Out Dil | 25,755 | 25,692 | 25,796 | 25,767 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3,261 | $3,571 | $4,261 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $12 | $9 | $10 |
| EBITDA | -$25,974 | -$22,958 | -$22,226 | -$24,428 |
| % Margin | – | – | -55,565% | – |